Altimmune (ALT) has received a new Sell rating, initiated by Goldman Sachs analyst, Corinne Johnson.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Corinne Johnson has given her Sell rating due to a combination of factors impacting Altimmune Inc. The primary concern is the company’s financial position, which poses significant challenges to the development of its lead asset, pemvidutide. This drug, a dual GLP-1/GCGR agonist, is being developed for obesity and related liver diseases, but it has not shown a distinct advantage over existing treatments in clinical trials.
Furthermore, the competitive landscape for such treatments is crowded, and Altimmune will need either a strategic partner or additional funding to continue its development efforts. The lack of a unique profile for pemvidutide, coupled with financial constraints, makes it difficult for Altimmune to successfully navigate the clinical development process necessary to bring the drug to market. These factors contribute to the Sell rating and the substantial downside risk reflected in the $1 price target.